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ABSTRACT
There is a lack of treatment options for many rare genetic disorders. Gene therapy represents a
promising and innovative approach to fill this gap. One of such rare disorders is incontinentia
pigmenti caused by X-linked deletions or mutations in the Nemo gene. The disease affects the skin,
teeth, and eyes and, most importantly, it leads to a severe vascular pathology of the central nervous
system. The genetic treatment of vascular disorders such as incontinentia pigmenti critically
depends on safe and efficient gene delivery. Thus, focus has been set on the development of
suitable vector systems. In a recent issue of EMBO Molecular Medicine, we describe the development
of a recombinant adeno-associated viral (AAV) vector with a unique tropism for the brain vascular
endothelium (termed AAV-BR1) and, as a proof of principle that may be transferred to other
vascular disorders, report on its therapeutic application in a mouse model of incontinentia
pigmenti. Here, we discuss the implications of our findings and further highlight the promising








AAV vectors for systemic application
Among the various viruses that are used as vector
systems, AAV has emerged as one of the most
favorable candidates for gene therapy.1 The intro-
duction of Glybera (alipogene tiparvovec), being
approved as first gene therapy drug of the Western
world by European regulatory authorities in 2012,
emphasizes the importance of AAV as a gene ther-
apy vector. In addition, Glybera as medication for
lipoprotein lipase deficiency (an orphan disease with
an incidence of below 1: 1,000,000) indicates that
gene therapy of rare diseases can be interesting both
from a medical and a pharmacoeconomic point of
view.2,3 Although the various AAV serotypes differ
in their tropism, none of the natural occurring AAV
serotypes is specific for one single tissue or cell
type.4 Thus, most AAV vectors must be adminis-
tered locally to the target tissue to enhance efficacy
and minimize side effects. Systemic vector adminis-
tration, however, is favorable for many diseases,
especially those affecting large organs (such as lung
and brain), or those having a disseminated pathol-
ogy (such as metastatic cancer). For gene therapy of
primary vascular or vascular-mediated diseases such
as hypertension, stroke, vascular dementia or multi-
ple sclerosis, systemic vector administration might
even be a mandatory prerequisite. Yet, systemic vec-
tor administration critically relies on safe, efficient
and target-specific vectors. The ongoing discussion
about hepatocellular carcinoma potentially being
induced by AAV highlights the importance of tar-
get-specific gene delivery.5,6 In our recent study
published in EMBO Molecular Medicine, we report
on the generation of a novel recombinant AAV vec-
tor, termed AAV-BR1, which specifically targets the
brain and the spinal cord where it predominantly
transduces blood-brain barrier (BBB)-associated
endothelial cells after intravenous injection in mice.7
Several systems have been developed and employed
to generate AAV vectors with improved tropism,
but only very few vectors have been proven to really
be suited for systemic target-specific gene therapy.
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The vascular endothelium as therapeutic target
Apart from unspecific (and functionally silent) particle
uptake in the reticular endothelial system of the spleen,
AAVBR1 has been shown to specifically home to the
brain after intravenous injection in mice. Even more
importantly, the strong AAV-BR1-mediated transgene
expression was restricted to the brain, and to lesser
extent the spinal cord and the eyes. At a cellular level,
AAV-BR1 predominantly transduced the BBB-
associated endothelium and sporadically some scat-
tered neurons. The endothelial transduction could be
reconfirmed in vitro on primary murine cells and,
albeit weaker, on immortalized human cerebral micro-
vascular endothelial cells (hCMEC/D3), a well charac-
terized cell line with blood-brain barrier (BBB)
properties.8 Interestingly, the transgene expression in
vivo was stable for the entire live span of mice (animals
were sacrified before their natural death at day 665
after vector injection to collect their organs). The abil-
ity to mediate such long lasting transgene expression
in the brain vascular endothelium renders AAV-BR1
very promising for gene therapy of neurovascular dis-
orders with the aim to improve cerebral perfusion. As
key players, endothelial cells are also the main target
to modulate the BBB or to study the barrier’s functions
in an experimental context.9 Although not examined
in our EMBO Molecular Medicine study, AAV-BR1
might potentially also be used to treat non-vascular
neurological disorders. In a previous study, it was
shown that AAV-mediated delivery of therapeutic
transgenes to brain endothelial cells can ameliorate the
pathology in mouse models of non-vascular-related,
rare neurological diseases (mucopolysaccharidosis
type VII and neuronal ceroid lipofuscinosis).10 Due to
the close proximity of endothelial cells and neurons,
the secretion of the transgene products (b-glucuroni-
dase and tripeptidyl peptidase I) from vector-trans-
duced endothelial cells into the brain parenchyma
presumably was sufficient to induce the observed ther-
apeutic effects. Thus, in our view, there is reason to
believe that vectors such as AAV-BR1 will be well
suited for similar approaches.
Treatment of incontinentia pigmenti
To test the therapeutic applicability of our AAV-BR1
vector, we chose a mouse model of incontinentia pig-
menti, a rare X-linked genetic disorder that mainly
affects the skin (also the nails, the hair, the teeth and
the eyes) and, most importantly, is accompanied by
severe neurological impairments.11 Deletions or muta-
tions in the NF-kB essential modulator (NEMO), a
key component of the NF-kB signal cascade, can lead
to death of brain endothelial cells, resulting in empty
tubes of basement membranes, so-called string vessels,
cerebral hypoperfusion, a disrupted BBB, and epileptic
seizures.12 Since there is no conventional therapy for
this disorder, we chose to employ the AAV-BR1 vec-
tor to substitute the missing genetic information in
neonatal heterozygous mice with germline deletion of
the X-chromosomal Nemo gene (Nemo¡/C) and in
adult animals with a conditional knockout of the
Nemo gene in brain endothelial cells (NemobeKO).
Using the AAV-BR1-NEMO vector, we were able to
significantly ameliorate the cerebrovascular pathology
of incontinentia pigmenti and to protect the brain
endothelial cells, seen as normalization of total vessel
length, reduction of string vessels to a normal level,
and reduced extravasation of albumin and immuno-
globulin into the brain parenchyma. Importantly, we
could show that transduction of brain endothelial cells
by the viral vector AAV-BR1 has no negative effects
on the integrity of the BBB, underlying the safety of
this approach. With regard to these promising results,
we are currently investigating the effect of our gene
therapy vector on other clinically relevant parameters
such as epileptiform events and seizures in the incon-
tinentia pigmenti mouse model.
Technical issues: Generating targeted vectors
from random AAV-display peptide libraries
Most approaches to redirect the tropism of AAV rely
on the modification of the viral capsid. One common
straight forward approach is the genetic incorporation
of or the chemical coupling to specific ligands (e.g., pre-
viously phage-selected peptides) or antibodies, as
reviewed in refs. 13, 14. This approach, however, has
the disadvantage to rely on the preexisting availability
of specific targeting agents, i.e. ligands or antibodies
which can lose their specificity when being transferred
into the AAV capsid. A promising alternative is an
approach called “directed evolution,” utilizing large
pools of AAV capsid variants (AAV libraries) that are
being screened in vitro or in vivo for desired properties.
Such AAV libraries either consist of shuffled capsid
proteins of different AAV serotypes, often accompanied
by further random mutations, e.g. by error-prone PCR,
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or they comprise pools of random peptides that are dis-
played on the AAV capsid in certain relevant posi-
tions.15-19 In theory, such libraries allow to select for
particles with the ability to target any unique structure
on the cell surface.15,20-22 The screening of random
AAV display peptide libraries is the only approach to
select peptides directly within the structural constraints
of the assembled AAV capsid. Our brain-targeted vec-
tor AAVBR1 was isolated from such a random library
with heptapeptide insertion in the capsid of AAV2 at a
position known to be relevant for receptor binding
(R588).17 In our view there are few important variables
which mainly determine the successful screening of a
random AAV library:
i) the library design and the exact insertion site, as
disruption of the natural receptor binding site is
essential
ii) the diversity of the library, as a high diversity
correlates with a high number of capsid var-
iants to choose from
iii) the number of selection rounds, as in each
round unspecific particles should decrease in
favor of specific ones
iv) the technique to identify the relevant particles
from the pool of remaining particles in the last
selection round, as even after several successful
selection rounds, the most common clone is
not always the most specific one
The AAV2 display peptide library used to screen
for brain vasculature-homing capsid variants had a
diversity of approx. 2x108 clones and AAV-BR1
was identified after 5 selection rounds with 2 d cir-
culation time each. As the “NRGTEWD” peptide
displayed by AAV-BR1 was part of the enriched
peptide sequence motif (XXGXXWX), it was
quickly identified as one of the most promising
variants. However, although carefully considering
all points mentioned above, in our experience the
identification of the best suited capsids still can be
difficult, as there might be no clear sequence motif.
In addition, unspecific capsid variants with an
advantage during library production might become
strongly enriched during selection. Thus, we further
improved the technique and recently described a
screening system based on next-generation
sequencing, accompanied by different rating scores
to identify the most relevant particles after selecting
random AAV display peptide libraries.22
Concluding remarks
There is huge potential for rare genetic disorders to
benefit from gene therapy in the near future. Despite
all drawbacks, our understanding of rare diseases is
growing and the available gene therapy tools are get-
ting better. Vector systems are being improved contin-
uously, and AAV provides a very promising platform.
In our recent study published in EMBO Molecular
Medicine, we could show that the screening of random
AAV display peptide libraries is a promising tech-
nique to generate truly tailored vectors.7 The produc-
tion of recombinant AAV2 vectors displaying the
brain-targeted NRGTEWD peptide (AAV-BR1) yields
comparable virus amounts to unmodified wildtype
AAV2 in repetitive experiments (in our hands in
approx. 1x1011 genomic particles from 1x107 HEK
293T cells after iodixanol purification). Thus, the
insertion of the NRGTEWD peptide does not seem to
negatively influence capsid assembly, which is note-
worthy since capsid-modified recombinant AAV vec-
tors sometimes suffer from poor virus production.
Although other AAV serotypes like AAV9 are known
to yield >10 fold higher titers than AAV2, the
amounts of recombinant AAV-BR1 that are needed
for gene therapy approaches can easily be produced in
few large scale preparations.23 The tropism of our
selected vector AAV-BR1 for BBB-associated endothe-
lial cells is unique and well suited for the treatment of
neurovascular diseases, which was proven by using
AAV-BR1 to normalize many of the severe neurologi-
cal impairments in a mouse model of incontinentia
pigmenti. Still, there are several open questions that
are worth to be investigated further. Up to now, we do
not know which receptor/s is/are utilized by AAV-
BR1 to specifically transduce brain endothelial cells. It
has been shown that the transmembrane protein
KIAA0319L is essential for cellular uptake of a variety
of AAV serotypes, apart from glycans that are com-
monly used by AAV for primary attachment 24,25
Therefore, this protein might also be important for
AAV-BR1. However, the sporadically observed AAV-
BR1-transduced neurons indicate that AAV-BR1
crosses the BBB to some extent, presumably via trans-
cytosis. Thus, it needs to be investigated which varia-
bles determine whether the vector is taken up by
endocytosis or crosses the BBB via transcytosis.
Experiments involving immunoprecipitation, micro-
arrays or targeted knockdown/ overexpression of
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candidate genes might help to answer these questions.
Another important aspect might become relevant
when thinking about the translation of the preclinical
mouse studies into the clinic. Although we have
shown that AAV-BR1 is able to transduce immortal-
ized human brain endothelial cells (hCMEC/D3) in
vitro, it is unclear whether the vector would also be
effective in human patients in vivo, as the situation in
vitro is not comparable to the in vivo situation. Taken
into culture, cells can dedifferentiate and change their
expression profile.26,27 Potential inter-species differen-
ces might also play a role as Chen et al. reported of
capsid-modified AAV vectors that even distinguish
between mice with a lysosomal storage disorder and
healthy litter mice of the same strain.10 Nonetheless,
the observed long-lasting and specific transgene
expression mediated by AAV-BR1 is unique and the
successful treatment of incontinenti pigmenti is very
promising, encouraging further studies. The finding
that target-specific particles can indeed be obtained by
selecting random AAV display peptide libraries in
vivo becomes even more important when considering
that such a selection can be performed on a variety of
organs or tissues, which we have recently confirmed
in another study choosing the lung as target organ.22
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